Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: $17.3 million Upfront Cash: Undisclosed
Deal Type: Financing January 28, 2020
Vascular Therapies plans to use the proceeds to further advance Sirogen, a proprietary sirolimus formulation for intraoperative, local, perivascular drug delivery.